Non-small cell lung cancer
The PBS subsidises crizotinib for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC).
Crizotinib can be subsidised through the Pharmaceutical Benefit Scheme (PBS) under section 85 of the National Health Act 1953 for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) NSCLC.
Patients must meet certain criteria in the restrictions and be eligible for the PBS.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing crizotinib.
Make all initial applications for authority approval to prescribe crizotinib for the treatment of Stage IIIB (locally advanced) or Stage IV (metastatic) NSCLC in writing and:
All applications must include a completed:
- authority prescription form, and
- ALK positive Non-Small Cell Lung Cancer PBS authority application form
Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.
For more information contact the PBS Complex Drugs Programs enquiry line.